Radhika Dalal

Radhika Dalal

Auto-generated profile, based on publicly available information

Radhika Dalal

Biophysics Graduate Program, University of California

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2023 in Nature Materials
Verified
Journal Article
Closed access
PDF file
ZLZhe Li
Zhe Li
SWShunzhi Wang
Shunzhi Wang
UNUna Nattermann
Una Nattermann
ABAsim K. Bera
Asim K. Bera
ABAndrew J. Borst
Andrew J. Borst
DBDavid Baker
David Baker

13 May 2025 in Blood
Verified
Journal Article
Open access
CKCorynn Kasap
Corynn Kasap
AIAdila Izgutdina
Adila Izgutdina
BPBonell Patiño-Escobar
Bonell Patiño-Escobar
AKAmrik Singh Kang
Amrik Singh Kang
NCNikhil Chilakapati
Nikhil Chilakapati
AWArun P. Wiita
Arun P. Wiita
Despite the success of BCMA-targeting CAR-Ts in multiple myeloma, patients with high-risk cytogenetic features still relapse most quickly and are in urgent need of additional therapeutic options. Here, we identify CD70, widely recognized as a favorable immunotherapy target in other cancers, as a specifically upregulated cell surface antigen in high-risk myeloma tumors. We use a structure-guided design to define a CD27-based anti-CD70 CAR-T design that outperforms all tested scFv-based CARs, leading to >80-fold improved CAR-T expansion in vivo. Epigenetic analysis via machine learning predicts key transcription factors and transcriptional networks driving CD70 upregulation in high-risk myeloma. Dual-targeting CAR-Ts against either CD70 or BCMA demonstrate a potential strategy to avoid antigen escape-mediated resistance. Together, these findings support the promise of targeting CD70 with optimized CAR-Ts in myeloma as well as future clinical translation of this approach.

10 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AKAmrik S Kang
Amrik S Kang
RDRadhika Dalal
Radhika Dalal
MLMingcheng Li
Mingcheng Li
AOAnupam Anand Ojha
Anupam Anand Ojha
SWSujata Walunj
Sujata Walunj
AWArun P. Wiita
Arun P. Wiita
CD70 is well-recognized as a promising "pan-cancer: chimeric antigen receptor (CAR) T-cell target. Prior work has shown that a "natural ligand" (NL)-based CAR targeting CD70, employing its physiological interaction partner CD27, may have therapeutic advantages over antibody-based CARs. Yet while antibody-based CARs are routinely optimized by affinity maturation of their scFv, whether the binding sequence of an NL CAR can be engineered to improve its function remains unexplored. Here, we combined deep learning with physics-based modeling to redesign residues at the CD27:CD70 interface, identifying a CD27 variant, "N88A", which enhances the efficacy of CD70-targeting CAR T-cells across models of acute myeloid leukemia, multiple myeloma, and renal cell carcinoma. Biophysical approaches, including molecular dynamics simulations, support a mechanism of increased binder conformational freedom underlying potency enhancement. Our work presents CD27N88A CAR T-cells as a promising new therapeutic option and proposes that computational modeling could be applied to enhance efficacy of other NL-based immunotherapies.